Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Buffalo, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 53 people enrolled
- Started
- 1 Dec 2019
- Ended
- 30 Mar 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- eszopiclone
- Brief behavioral therapy for insomnia
- Record updated
- 21 October 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Age >18 years and <65 years old
- Diagnosis of PTSD as determined by the intake conducted through the PTSD Clinic or the Mental Health Clinic
- Documented obstructive sleep apnea by polysomnography (AHI 5 or more/hour) who are non-adherent to CPAP as defined by device usage of less than 4 hours per night
- Chronic ( 3 months' duration) insomnia disorder
- Psychotherapeutic treatment stable for at least 4 weeks prior to randomization
- Capable of giving informed consent
Who cannot take part
- Use of potent cytochrome p450 3A4 inhibitor medications (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) and is unwilling or it is clinically contraindicated to stop the medication
- History of narcolepsy and/or cataplexy
- Treatment for seizure disorders
- History of clinically significant hepatic impairment
- History of hypersensitivity, intolerance, or contraindication to eszopiclone
- Diagnosis of current schizophrenia or schizoaffective disorder
- Diagnosis of a substance dependence/abuse disorder in the past year
- History of complex nocturnal behaviors while using eszopiclone
- Severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others
- Diagnosis of bipolar disorder
- Insomnia secondary to pain
- Pregnant or lactating
- Unwilling to try or use CPAP
- Consumption of more than two alcoholic beverages per night
- Documented or self-reported resolution of insomnia from current behavioral or pharmacological treatment of insomnia
Where in United States
- VA Western New York Healthcare System, Buffalo, NYBuffalo, United States
About the trial
What the trial wants to find out
Obstructive sleep apnea (OSA) is commonly reported in Veterans with post-traumatic stress disorder, which can potentiate symptoms of anxiety and depression, daytime symptoms and worsen nightmares. Continuous positive airway pressure (CPAP) is the most effective therapy but adherence to treatment is suboptimal. Insomnia is considered a barrier to long-term adherence. The overarching theme of the proposal is to compare the effectiveness of cognitive behavioral therapy for insomnia (CBT) plus eszopiclone, a nonbenzodiazepine hypnotic, versus CBT alone in Veterans with PTSD who are diagnosed with both OSA and insomnia, using a randomized, clinical trial, on sleep quality of life, PTSD severity, and CPAP adherence.
The 2 groups in the trial
- BBTI plus eszopicloneTreatment being tested
participants randomized to the combination therapy will receive eszopiclone 2 mg orally at bedtime or placebo starting with the BBTI sessions for a period of 2 weeks in combination with 4 sessions of BBTI over 4 weeks.
Treatment: eszopiclone and Brief behavioral therapy for insomnia
- Brief Behavioral Therapy for InsomniaExisting treatment, for comparison
participants randomized to BBTI will receive 4 sessions of BBTI over 4 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pragmatic Randomized Comparator Trial of Eszopiclone and Brief Behavioral Therapy for Insomnia in CPAP Non Adherent Veterans With PTSD and Complex Insomnia
- Publications
- Record updated
- 21 October 2025